Literature DB >> 11374135

Lipid abnormalities in chronic renal failure patients undergoing hemodialysis.

N T de Gómez Dumm1, A M Giammona, L A Touceda, C Raimondi.   

Abstract

Lipid abnormalities are common in patients with renal disease, probably contributing to the high incidence of cardiovascular diseases in this population. In this study we determined the plasma and erythrocyte lipid profile in patients with chronic renal failure (CRF) along 30 months under hemodialysis. In the same patients the influence of cuprophane and polysulfone dialysis membranes on the fatty acid pattern of plasma and erythrocytes, before and after dialysis, was also studied. Fluidity in erythrocyte membranes was also assessed by diphenylhexatriene (DPH) fluorescence polarization measurements. Triglyceride levels were increased in the plasma and in erythrocyte membranes of CRF patients compared to healthy subjects. Plasma polyunsaturared fatty acids decreased whereas palmitic and monounsaturated acids increased in CRF patients. No changes were observed in either the fatty acid profile or DPH fluorescence anisotropy of erythrocyte membranes. The lipid composition abnormalities persisted after 18 months and they became more notorious after 30 months. Neither the plasma nor the erythrocyte membrane lipid pattern changed in CRF patients during the dialysis session, regardless of the dialysis membrane used. We conclude that CRF patients under regular hemodialysis evidence a gradual deterioration in the fatty acid and triglyceride abnormalities, a finding that might be relevant to the risk of cardiovascular disease in this setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374135

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  7 in total

1.  Epigallocatechin-3-gallate affects the growth of LNCaP cells via membrane fluidity and distribution of cellular zinc.

Authors:  Jun-guo Yang; Hai-ning Yu; Shi-li Sun; Lan-cui Zhang; Guo-qing He; Undurti N Das; Hui Ruan; Sheng-rong Shen
Journal:  J Zhejiang Univ Sci B       Date:  2009-06       Impact factor: 3.066

2.  Effects of hemodialysis on blood fatty acids.

Authors:  Benjamin Gollasch; Inci Dogan; Michael Rothe; Maik Gollasch; Friedrich C Luft
Journal:  Physiol Rep       Date:  2020-01

3.  Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine.

Authors:  Nelva T de Gómez Dumm; Ana M Giammona; Luis A Touceda
Journal:  Lipids Health Dis       Date:  2003-09-18       Impact factor: 3.876

4.  Assessment of dyslipidemia in pre-dialysis patients in south-west Nigeria.

Authors:  Effiong Ekong Akpan; Udeme Ekpenyong Ekrikpo; Emmanuel Edet Effa; Aniema Isaac Assam Udo; Solomon Kadiri
Journal:  Niger Med J       Date:  2014-05

5.  Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics.

Authors:  Feng Yan; Zhensong Wen; Rui Wang; Wenling Luo; Yufeng Du; Wenjun Wang; Xianyang Chen
Journal:  BMC Pulm Med       Date:  2017-12-06       Impact factor: 3.317

6.  Blood Fatty Acid Status and Clinical Outcomes in Dialysis Patients: A Systematic Review.

Authors:  Ban-Hock Khor; Sreelakshmi Sankara Narayanan; Karuthan Chinna; Abdul Halim Abdul Gafor; Zulfitri Azuan Mat Daud; Pramod Khosla; Kalyana Sundram; Tilakavati Karupaiah
Journal:  Nutrients       Date:  2018-09-21       Impact factor: 5.717

Review 7.  Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis.

Authors:  Elena Bargagli; Rosa Metella Refini; Miriana d'Alessandro; Laura Bergantini; Paolo Cameli; Lorenza Vantaggiato; Luca Bini; Claudia Landi
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.